EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Willow Biosciences Inc (CANSF) fair value: what the stock is really worth

As of Sep 11, 2026: fair value of Willow Biosciences Inc $0.03, price $0.08, upside -56.1%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Energy · US

WB Willow Biosciences Inc logo Thin data Sep 23, 2026

Willow Biosciences Inc

CANSF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0344 · Strongly overvalued (−56%)
!Quality 43/100
!Mixed Growth (revenue 5y +133.4 %/yr)
!Low debt · negative free cash flow
!Trails peers (3/9)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Willow Biosciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.25 $0.0135 Fair Value $0.0344 Jan 2020 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.0135 – $8.25 · fair‑value band $0.0277 – $0.0411 · the $0.0784 price screens above the $0.0344 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Willow Biosciences in your weekly email

Every Wednesday you see whether Willow Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Atlas Energy Corp. operates as an international upstream royalty and streaming company. It focuses on the identification, acquisition, and management of upstream oil and gas royalty and streaming transactions. The company was formerly known as Willow Biosciences Inc. and changed its name to Atlas Energy Corp. in June 2025. Atlas Energy Corp.

Show more

Atlas Energy Corp. operates as an international upstream royalty and streaming company. It focuses on the identification, acquisition, and management of upstream oil and gas royalty and streaming transactions. The company was formerly known as Willow Biosciences Inc. and changed its name to Atlas Energy Corp. in June 2025. Atlas Energy Corp. is headquartered in Calgary, Canada.

Stock analysis

Willow Biosciences Inc (CANSF) currently trades at $0.0784, while our model-based Fair Value estimate is $0.0344, implying the stock looks roughly 127.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0277 (bear) to $0.0411 (bull), the price of $0.0784 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Energy sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Willow Biosciences Inc reported revenue of C$0 in FY2025 versus C$133K in FY2021. Reported net income was −C$1.4M in FY2025.

Key figures

Market cap $67.4M · P/S ratio 14.4 · Return on equity −27.8% · Return on assets (EBIT) −93.4% · Revenue (TTM) $4.7M · Revenue growth (YoY) +33.5% · Free cash flow −C$3.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Energy peers we cover trades at −11% fair-value upside, at −56%, CANSF screens richer than that median.

Fair Value models

Bear $0.0277 Fair Value $0.0344 Bull $0.0411
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0200 $0.0300 $0.0400 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0200 $0.0300 $0.0400 54

Open the full fair value analysis →

Notify me when CANSF reaches fair value

Put CANSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 53 · Market factors (momentum, volatility) 5

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 16
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 3
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+42.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+389.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+133.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−9,723.7% (2018) → −1,149.9% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CANSF screens 128% overvalued. Compare with Enbridge Inc →

Compare Willow Biosciences Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Oil & Gas Midstream · 85 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside −56% · Bottom 25%
Profitability
Return on assets −17% · Bottom 25%
Operating margin (TTM) 0% · Bottom 25%
Growth and dividend
Revenue growth 33% · Above median
Balance sheet
Debt / equity 0.03× · Lowest 25%

Valuation Multiplesvs Oil & Gas Midstream median · lower = cheaper

P/B 2.47× · Pricier than median
P/S (TTM) 14.45× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 24
FUTURE (revenue growth)100 · sector 60
PAST (return on equity)0 · sector 45
HEALTH (low debt)99 · sector 52
DIVIDEND (yield)0 · sector 81

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Oil & gas

Similar stocks

10 more Oil & Gas Midstream stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Enbridge Inc ENB $47.35 $36.91 −22%
The Williams Companies, Inc WMB $71.11 $11.73 −84%
Enterprise Products Partners L.P. EPD $37.57 $24.61 −34%
Kinder Morgan, Inc KMI $31.37 $28.24 −10%
TC Energy Corporation TRP $59.78 $24.51 −59%
Energy Transfer LP, ET $20.49 $19.43 −5%
MPLX LP owns and MPLX $58.81 $70.84 +20%
ONEOK, Inc OKE $90.54 $80.35 −11%
Targa Resources Corp TRGP $282.15 $79.61 −72%
Cheniere Energy, Inc LNG $273.61 $349.73 +28%

Explore undervalued stocks

More undervalued Energy stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Willow Biosciences Inc · Fair Value
$0.0344 −128%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Willow Biosciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/CANSF

Frequently asked questions

Is Willow Biosciences Inc (CANSF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0344 versus the last price from Sep 11, 2026 of $0.0784, about −56% upside (overvalued).
What is the fair value of CANSF?
Our model-based fair value for Willow Biosciences Inc is $0.0344 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 11, 2026): $0.0784.
What is the quality score of CANSF?
Willow Biosciences Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Willow Biosciences Inc (CANSF)?
Our model-based price target is the fair value of $0.0344 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $0.0277, optimistic scenario $0.0411. It is a calculation from audited fundamentals, not an analyst target.
What is the Willow Biosciences Inc stock forecast for 2026?
Our models put fair value at $0.0344, about −56% upside versus the last price from Sep 11, 2026 of $0.0784 (overvalued). Cautious scenario $0.0277, optimistic scenario $0.0411. The calculation is refreshed regularly with new filings.
What is the revenue of Willow Biosciences Inc (CANSF)?
Willow Biosciences Inc reported trailing-twelve-month revenue of about $4.7M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Willow Biosciences Inc (CANSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Willow Biosciences Inc it is $0.0344 per share (as of Sep 23, 2026), against a price of $0.0784. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Willow Biosciences Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CANSF trades above its calculated fair value: price $0.0784, fair value $0.0344, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CANSF?
No. The price is what the market pays today ($0.0784); the fair value is what the company's own numbers justify ($0.0344). For Willow Biosciences Inc the two are $0.0440 per share apart. That gap is exactly why we show both numbers side by side.
How much is Willow Biosciences Inc worth?
The market values Willow Biosciences Inc at about $67.4M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0784; our models calculate a fair value of $0.0344 per share.
What do the bullish and bearish scenarios say about CANSF?
Our models span a range for Willow Biosciences Inc: cautious scenario $0.0277, base $0.0344, optimistic $0.0411 per share (as of Sep 23, 2026, price $0.0784). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Willow Biosciences Inc (CANSF)?
Balance-sheet figures for Willow Biosciences Inc (as of Sep 23, 2026): return on equity −27.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is CANSF from its 52-week high?
Willow Biosciences Inc trades at $0.0784, about 49% below its 52-week high of $0.1523 and at the low of $0.0784 (as of Sep 11, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0344 is for.
Which stocks are comparable to Willow Biosciences Inc?
From the same area (Energy) we also value Enbridge Inc, The Williams Companies, Inc, Enterprise Products Partners L.P., Kinder Morgan, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Willow Biosciences Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0784, calculated fair value $0.0344 (−56%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CANSF calculated?
We run Willow Biosciences Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0344, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Willow Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Willow Biosciences Inc (CANSF)?
The latest price we hold is from Sep 11, 2026 and stands at $0.0784. Our model-based fair value is $0.0344, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Willow Biosciences Inc right now?
The price sits above even our optimistic bull case ($0.0411). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Willow Biosciences Inc

How large is the market capitalisation of Willow Biosciences Inc (CANSF)?
The market capitalisation of Willow Biosciences Inc is $67.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Willow Biosciences Inc (CANSF)?
The price-to-sales ratio of Willow Biosciences Inc is 14.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Willow Biosciences Inc (CANSF)?
The return on equity (ROE) of Willow Biosciences Inc is −27.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Willow Biosciences Inc (CANSF)?
On an EBIT basis the return on assets of Willow Biosciences Inc is −93.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Willow Biosciences Inc (CANSF)?
Revenue at Willow Biosciences Inc is growing +33.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Willow Biosciences Inc (CANSF) generate?
The free cash flow of Willow Biosciences Inc is −C$3.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Willow Biosciences Inc in the live analysis

One click puts Willow Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.